Nyxoah (ENXTBR:NYXH) Stock Faces Cash Burn Questions After Sales Surge

Nyxoah walked into this earnings day with a bruised share price, down sharply over the past quarter and sitting at €1.152 at Thursday’s close. The stock looks priced as if the balance sheet and losses might overwhelm the sleep apnea story. The headline from Q2 tells a different tale. Revenue reached €7.675m and gross margin sat at 60%, while operating losses remained heavy. For investors, the gap between a weak share price and a business that is now generating meaningful sales is the core tension to watch from here.

Impressed by Nyxoah’s 60% gross margin but uneasy about the ongoing operating losses and pressure on the share price? You may want to consider balancing your portfolio with 302 resilient stocks with low risk scores.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): €7.675m vs. €1.34m (very large increase, more than 5x year on year)
• Net Loss (Q2 2026 vs Q2 2025): €32.964m loss vs. €20.607m loss (loss widened by 60%)
• Basic EPS (Q2 2026 vs Q2 2025): €0.578 loss per share vs. €0.550529 loss per share (loss per share widened by 5%)
• Gross Margin (Q2 2026): 60% for the quarter, reflecting Nyxoah’s current mix of U.S. and international sales

Tired of scrolling through dense earnings releases and raw figures to piece together what Nyxoah is really doing? View a clear visual summary of Nyxoah’s revenue trends and profitability profile in the full company report for Nyxoah.

Evaluating Nyxoah’s Execution Against Bullish Claims

The optimistic view on Nyxoah is that a focused U.S. rollout of Genio can quickly build a high quality implant funnel and move the business toward scale. Q2 gives concrete proof points. U.S. revenue reached €5.2m, with worldwide gross margin at 60%, which lines up with the idea that higher utilization at targeted centers can support healthier unit economics.

Operational milestones are also tracking the bullish script. The company exited Q2 with 262 surgeons trained and 180 active high volume accounts, roughly double the prior quarter’s footprint. The 427 patients sitting in prior authorization entering Q3, following what management describes as strong conversion from authorizations to implants, shows the funnel is filling in line with the training and account build out. Internationally, management reports Germany already at breakeven, which supports the argument that selected markets can cover their own growth investments.

Compare Nyxoah’s growing surgeon network and 60% gross margin with how institutional analysts are positioning price targets. See the consensus price target analysis for Nyxoah to check whether Wall Street expectations are keeping pace with the operational story.

Nyxoah Bear Case: Cash Burn And Execution Scrutiny

The bearish view on Nyxoah is clear. U.S. rollout and reimbursement could move too slowly while cash burn and funding needs keep rising. This quarter only partly challenges that view. Revenue reached €7.7m with 60% gross margin and accounts and surgeons expanded quickly. That shows commercial traction. However, operating loss remained heavy at €20.6m and management nudged full year operating expense guidance up to €99m to €102m. Non GAAP cash operating expense held at €88m to €90m. That implies no visible step toward operating leverage yet.

Bears also worry about funding risk and dilution. Liquidity improved to about €97.8m after a €95m equity raise and €15m from the European Investment Bank, but this directly ties progress to external capital. With the share price down over 50% across 90 days, the market reaction still leans toward caution on these unresolved milestones.

After heavy cash burn, a short cash runway and recent dilution, many investors ask if this is only the start of deeper structural issues. Review our independent risk analysis for Nyxoah which shows 4 important warning signs

Stay Ahead With Simply Wall St

If Nyxoah’s mix of strong gross margin and heavy losses has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch how the story evolves. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the most important updates to your holdings. For a broader view, tap into the Community to see how other investors are thinking about Nyxoah and stocks facing similar trade offs. By spotting potential catalysts and risks early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Nyxoah?

Fresh stock ideas can move from quiet to breakout quickly. Use these under the radar for now lists before the best entry points are gone. Act now.

• Identify cash generative compounders early by reviewing the curated 255 high quality undervalued stocks, which may still be flying below wider market momentum.
• Explore structural shifts in power demand by scanning the hand picked 37 power grid technology and infrastructure stocks before attention shifts more fully to the sector.
• Monitor potential upside from advanced automation by checking the focused 36 robotics and automation stocks while these stories are still developing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com